mapracorat Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Mapracorat is an anti-inflammatory drug belonging to the experimental class of selective glucocorticoid receptor agonists (SEGRAs). It is in clinical trials for the topical treatment of atopic dermatitis, inflammation following cataract surgery, and allergic conjunctivitis. Preliminary investigation for the treatment of keratoconjunctivitis sicca has been conducted in cellular models.   Wikipedia

Chemistry

  • SMILES: Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1
  • InChIKey: VJGFOYBQOIPQFY-XMMPIXPASA-N
  • Mol. Mass: 462.49
  • ALogP: 5.69
  • ChEMBL Molecule:
    mapracorat  
More Chemistry

Pharmacology

Alternative names

bol 303242-x | bol-303242-x | bol303242-x | mapracorat | r-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methyl-2-(((2-methyl-5-quinolyl)amino)methyl)pentan-2-ol | zk245186 | zk 245186 | zk-245186

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Cataract (Phase 3)

Conjunctivitis, Allergic (Phase 2)

Corneal Endothelial Cell Loss (Phase 1)

Dermatitis, Atopic (Phase 2)

Dry Eye Syndromes (Phase 2)

Eczema (Phase 2)

General Surgery (Phase 3)

Inflammation (Phase 3)

Pain (Phase 3)

Psoriasis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue